The relationship between bleeding and adverse outcomes in ACS and PCI: pharmacologic and nonpharmacologic...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Antithrombotic therapy (antiplatelet, antithrombin agents) is crucial for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
• These therapies increase bleeding risk, which is associated with adverse outcomes, including mortality.
• Optimizing patient outcomes requires a better understanding of bleeding complications and risk factors.

Purpose of the Study:

• To define bleeding criteria and assess its correlation with adverse outcomes.
• To compare the impact of bleeding versus ischemic events (e.g., myocardial infarction) on mortality.
• To explore the relationship between bleeding and treatment modifications, and methods for prediction and prevention.

Main Methods:

• Review of definitions, severity, and types of bleeding complications.
• Analysis of patient characteristics, clinical presentations, and treatment variables associated with bleeding risk.
• Exploration of pharmacological and nonpharmacological strategies to minimize bleeding risk.

Main Results:

• Bleeding complications are significantly associated with increased mortality in patients receiving antithrombotic therapy.
• The risk of bleeding must be balanced against the efficacy of antithrombotic agents to prevent ischemic events.
• Understanding bleeding risk factors is essential for modifying long-term treatment strategies.

Conclusions:

• Improved understanding of bleeding is critical for optimizing antithrombotic therapy in ACS and PCI patients.
• Strategies to predict and prevent bleeding are necessary to improve patient outcomes and reduce mortality.
• Balancing antithrombotic efficacy with bleeding risk is paramount in clinical decision-making.